GlassScriptPhysician profile
Edwin P Schulhafer
NPI 1205886785
$1,898.73
in general payments reported to CMS, 2019-2025
18 companies · $162 in 2025
The $162 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $150 · 2020: $210 · 2021: $155 · 2022: $590 · 2023: $460 · 2024: $172 · 2025: $162.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $794.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $794.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $609.58 | 2019-2025 | |
| Glaxosmithkline, LLC. | $385.35 | 2019-2024 | Trelegy Ellipta, Arexvy, Nucala |
| Astrazeneca Pharmaceuticals LP | $289.84 | 2019-2025 | Fasenra, Tezspire |
| Philips North America LLC | $101.37 | 2022 | |
| Amgen INC. | $75.68 | 2022-2025 | Tezspire |
| Sanofi-Aventis U.S. LLC | $59.99 | 2022 | |
| Pfizer INC. | $52.40 | 2019-2023 | |
| Teva Pharmaceuticals USA, INC. | $51.73 | 2020-2023 | |
| Ars Pharmaceuticals Operations, INC. | $47.69 | 2025 | Neffy |
| Novartis Pharmaceuticals Corporation | $34.63 | 2020-2025 | |
| Kaleo, INC. | $31.06 | 2023 | Auvi-Q |
| Takeda Pharmaceuticals U.S.A., INC. | $30.04 | 2020-2024 | Takhzyro |
| Abbvie INC. | $28.14 | 2021-2023 | Rinvoq |
| Leo Pharma INC. | $27.07 | 2022 | |
| Aimmune Therapeutics, INC. | $26.06 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.14 | 2020 | |
| Genentech USA, INC. | $16.13 | 2024 | Xolair |
| Regeneron Healthcare Solutions, INC. | $14.83 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edwin Schulhafer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.